The global hypoactive
sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.
About one-quarter of patients treated with Vyleesi had an increase of 1.2 or more in their
sexual desire score (scored on a range of 1.2 to 6.0, with higher scores indicating greater
sexual desire), compared with about 17% of those who took placebo.
According to the companies, Vyleesi is the first US FDA-approved product for the treatment of premenopausal women who experience distress or interpersonal difficulty due to low
sexual desire. Vyleesi is believed to bind to melanocortin receptors in the central nervous system that are thought to be associated with sexual function.
Instead, women with HSDD have "previously experienced no problems with
sexual desire," the FDA said.
But if sex is so central to who humans are as embodied, loving beings that it continues in heaven, then it follows that believers have an obligation to cultivate
sexual desire, and churches should be helping them do that.
The researchers concluded that experiencing
sexual desire between previously unacquainted strangers may help facilitate behaviours that cultivate personal closeness and bonding.
In 2015, the Food and Drug Administration approved flibanserin (Addyi) as the first treatment for hypoactive
sexual desire disorder in premenopausal women.
Flibanserin could help premenopausal women who have distressing low
sexual desire, which must be acquired and generalized:
This report provides comprehensive information on the therapeutic development for Female Hypoactive
Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
In a series of three phase III clinical trials in North America, premenopausal women who met the DSMTV diagnostic criteria for hypoactive
sexual desire disorder (HSDD) and who were in a stable monogamous relationship took flibanserin or placebo.
KEY WORDS:
sexual desire; desire discrepancy; sexual satisfaction; low desire